These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12544982)

  • 1. Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.
    Eichacker PQ; Natanson C
    Crit Care Med; 2003 Jan; 31(1 Suppl):S94-6. PubMed ID: 12544982
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
    Rudis MI; Fish DN
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.
    Bernard GR
    Crit Care Med; 2003 Jan; 31(1 Suppl):S85-93. PubMed ID: 12544981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 5. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
    Eichacker PQ; Danner RL; Suffredini AF; Cui X; Natanson C
    Crit Care Med; 2005 Oct; 33(10):2426-8. PubMed ID: 16215410
    [No Abstract]   [Full Text] [Related]  

  • 6. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical trials in severe sepsis with drotrecogin alfa (activated).
    Laterre PF
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S5. PubMed ID: 18269692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drotrecogin alfa on trial.
    Tillotson GS
    Lancet Infect Dis; 2009 Jan; 9(1):2-3. PubMed ID: 19095188
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 10. Substantiating the concerns about recombinant human activated protein C use in sepsis.
    Deans KJ; Minneci PC; Banks SM; Natanson C; Eichacker PQ
    Crit Care Med; 2004 Dec; 32(12):2542-3. PubMed ID: 15599164
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant human activated protein C in severe sepsis.
    Mann HJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S19-23. PubMed ID: 11885409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis.
    Olsen KM; Martin SJ
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):196S-205S. PubMed ID: 12492226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.
    Doig CJ; Laupland KB; Zygun DA; Manns BJ
    Expert Opin Pharmacother; 2003 Oct; 4(10):1789-99. PubMed ID: 14521488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 15. Kigris. FDA approves first biologic for sepsis.
    Nursing; 2002 Feb; 32(2):18. PubMed ID: 11924158
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe sepsis and therapy with activated protein C.
    Parrillo JE
    N Engl J Med; 2005 Sep; 353(13):1398-400. PubMed ID: 16192486
    [No Abstract]   [Full Text] [Related]  

  • 17. Activated protein C: do more survive?
    Macias WL
    Intensive Care Med; 2006 Apr; 32(4):605-7; author reply 610-2. PubMed ID: 16508756
    [No Abstract]   [Full Text] [Related]  

  • 18. Activated protein C: do more survive?
    Ridley S
    Intensive Care Med; 2006 Apr; 32(4):608; author reply 610-2. PubMed ID: 16508755
    [No Abstract]   [Full Text] [Related]  

  • 19. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise.
    Carlet J
    Crit Care Med; 2006 Feb; 34(2):525-9. PubMed ID: 16424736
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant human-activated protein C (rhAPC) in childhood sepsis.
    Frassica JJ; Vinagre YM; Maas B
    J Intensive Care Med; 2004; 19(1):56-7. PubMed ID: 15035756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.